Literature Scan

Literature Scan

New and noteworthy research from the medial literature landscape

Pomalidomide Does Not Significantly Improve RBC Transfusion Needs in Myelofibrosis

Anemia occurs commonly in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF), and such patients are often red blood cell (RBC) transfusion-dependent. No therapy approved...

Finding the Best VTE Prophylaxis Options for Patients Undergoing Total Hip and Knee Replacement

For prophylaxis against venous thromboembolism (VTE) after total hip replacement (THR) or total knee replacement (TKR), guidelines from the American College of Chest Physicians...

Blinatumomab Versus Standard-of-Care Chemotherapy in Acute Lymphocytic Leukemia

In a multinational, prospective, randomized, phase III study, investigators found that the anti-CD19/CD3 bispecific T-cell engager antibody blinatumomab improved survival outcomes, compared with standard-of-care...

Long-Term Follow-Up Confirms Safety, Efficacy of Imatinib for CML

Early results (published in Leukemia in 2009) from the phase III International Randomized Study of Interferon and STI571 (IRIS) demonstrated that imatinib 400 mg...

Deep Response With Venetoclax Plus Rituximab in Relapsed/Refractory CLL

Combining the selective BCL2 inhibitor venetoclax with rituximab may increase the depth and durability of response in patients with relapsed/refractory chronic lymphocytic leukemia (CLL),...

Aplastic Anemia Nearly Triples Risk of VTE

The systemic inflammation that characterizes aplastic anemia (AA) may also contribute to a greater risk of venous thromboembolism (VTE), giving patients with AA a...

Idelalisib Combination Improves PFS But Increases Infection Risk in Relapsed/Refractory CLL

According to a randomized, placebo-controlled, phase III study published in the Lancet Oncology, adding idelalisib to the combination of bendamustine and rituximab (BR) nearly...

AML and Other Myeloid Neoplasms According to WHO A Look at the Revised Classification

In June 2016 the World Health Organization (WHO) updated its 2008 classification of tumors of the hematopoietic and lymphoid tissues. The revised myeloid disorders...

Rivaroxaban Beats Aspirin in Reducing Risk of Recurrent VTE, Even at Lower Doses

Patients with venous thromboembolism (VTE) require anticoagulation, but concerns about bleeding have complicated decisions about using higher- or lower-intensity anticoagulation or aspirin for subsequent...

Identifying Genetic Mutations That Can Predict Transplant Outcome in Patients With Myelodysplastic Syndromes

Though allogeneic hematopoietic cell transplantation (alloHCT) is the only curative option for myelodysplastic syndromes (MDS), transplant-related mortality, complication rates, and available, suitable donors preclude...
Advertisement

Current Issue

July 2017, Volume 3, Issue 8

This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.